{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:17:07Z","timestamp":1788157027122,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To evaluate and compare the efficacy and safety of interferon alpha-2a (IFN-\u03b12a) and cyclosporine-A (CsA) in patients with refractory Beh\u00e7et\u2019s uveitis (BU).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this 12-month randomized, controlled, prospective trial, 26 participants (44 eyes) completed the study. Patients were randomly allocated to the IFN-\u03b12a or CsA groups. All patients in both groups received a standardized prednisone burst and tapering schedule as per protocol. The primary outcome measures were response rate, complete remission rate, and tolerance rate. The secondary outcome measures included time to achieve complete remission, the logarithm of the minimum angle of resolution (logMAR) of best-corrected visual acuity (BCVA), and Beh\u00e7et\u2019s disease ocular attack score 24 (BOS24). T-tests and non-parametric tests were used to compare quantitative variables, and chi-square tests were performed to compare qualitative variables.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The response and complete remission rates were 85.7% (12\/14 patients) and 50.0% (7\/14 patients) in the IFN-\u03b12a group, compared with 66.7% (8\/12 patients) and 25.0% (3\/12 patients) in the CsA group, respectively (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Complete remission was achieved at 3.3 and 7.0\u00a0months after initiation of IFN-\u03b12a and CsA (<jats:italic>p<\/jats:italic> = 0.023). LogMAR BCVA significantly improved 1\u00a0month after IFN-\u03b12a initiation (23 eyes) (<jats:italic>p<\/jats:italic> = 0.002), and this beneficial effect remained statistically significant during the entire follow-up period (<jats:italic>p<\/jats:italic> &amp;lt; 0.05); however, this improvement was not observed in the CsA group (21 eyes). At the endpoint, LogMAR BCVA in the IFN-\u03b12a group was significantly better (0.22 vs. 0.31, <jats:italic>p<\/jats:italic> = 0.031) with a higher improvement rate (60.9 vs. 47.6%, <jats:italic>p<\/jats:italic> &amp;gt; 0.05). Moreover, compared to the CsA group, more eyes in the IFN-\u03b12a group had a lower BOS24 score (87.0 vs. 57.1%, <jats:italic>p<\/jats:italic> = 0.042). None of the patients had any side effects that influenced the medication adherence.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Compared to CsA plus corticosteroid, IFN-\u03b12a plus corticosteroid appears to induce a better treatment response, a significantly greater improvement in visual acuity, and more stable remission of intraocular inflammation in a 12-month study period.<\/jats:p>","DOI":"10.3389\/fphar.2021.699903","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T06:19:46Z","timestamp":1626675586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of the Safety and Efficacy of Interferon Alpha-2a and Cyclosporine-A When Combined With Glucocorticoid in the Treatment of Refractory Beh\u00e7et\u2019s Uveitis: A Randomized Controlled Prospective Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Yujing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghang","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"B1","first-page":"136","article-title":"Evaluation of Conventional Therapy versus Cyclosporine A in Beh\u00e7et\u2019s Syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transpl. Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0929-5","article-title":"Conventional Immunosuppressive Therapy in Severe Behcet\u2019s Uveitis: the Switch Rate to the Biological Agents","volume":"18","author":"Celiker","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review","volume":"52","author":"Chighizola","year":"2017","journal-title":"Clinic Rev. Allerg Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a Collaborative Study of 27 Countries on the Sensitivity and Specificity of the New Criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2020.1815797","article-title":"Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Beh\u00e7et\u2019s Uveitis: Customizing Therapy According to the Clinical Features","volume":"6","author":"De Simone","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term Remission after Cessation of Interferon-\u03b1 Treatment in Patients with Severe Uveitis Due to Beh\u00e7et\u2019s Disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term Efficacy of Interferon in Severe Uveitis Associated with Beh\u00e7et Disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/09273948.2019.1587473","article-title":"The Results of Interferon-Alpha Treatment in Beh\u00e7et Uveitis","volume":"28","author":"Eser-Ozturk","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current Concepts in the Etiology and Treatment of Beh\u00e7et Disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et\u2019s Disease: New Insights into Pathophysiology, Clinical Features and Treatment Options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term Efficacy and Safety of Low-Dose Interferon Alpha2a Therapy in Severe Uveitis Associated with Beh\u00e7et Disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon Alpha-2a Therapy in Patients with Refractory Beh\u00e7et Uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 Update of the EULAR Recommendations for the Management of Beh\u00e7et\u2019s Syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1755-3768.2011.02348.x","article-title":"Light on the Horizont: Biologicals in Beh\u00e7et Uveitis","volume":"91","author":"Hazirolan","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working GroupStandardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","article-title":"Beh\u00e7et\u2019s Disease Ocular Attack Score 24: Evaluation of Ocular Disease Activity before and after Initiation of Infliximab","volume":"58","author":"Kaburaki","year":"2014","journal-title":"Jpn. J. Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","article-title":"Long-term Efficacy and Safety of Interferon \u03b1-2a Therapy in Severe Refractory Ophthalmic Behcet\u2019s Disease","volume":"35","author":"Kavandi","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The Use of Interferon \u03b1 in Beh\u00e7et Disease: Review of the Literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human Recombinant Interferon Alfa-2a for the Treatment of Behcet\u2019s Disease with Sight Threatening Posterior or Panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"B20","first-page":"896","article-title":"Longterm Visual Prognosis of Patients with Ocular Adamantiades-Beh\u00e7et\u2019s Disease Treated with Interferon-Alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12886-018-0719-0","article-title":"Interferon Alpha-2a Treatment for Refractory Behcet Uveitis in Korean Patients","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(89)92381-7","article-title":"Double-masked Trial of Cyclosporin versus Colchicine and Long-Term Open Study of Cyclosporin in Beh\u00e7et\u2019s Disease","volume":"333","author":"Masuda","year":"1989","journal-title":"The Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10792-013-9788-5","article-title":"Current and Future Treatments for Beh\u00e7et\u2019s Uveitis: Road to Remission","volume":"34","author":"Mesquida","year":"2014","journal-title":"Int. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs. Tacrolimus Therapy for Posterior and Intermediate Uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch. Ophthalmol. (Chicago, Ill. 1960)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/247345","article-title":"Behcet\u2019s Disease: Systemic and Ocular Manifestations","volume":"2013","author":"Paovic","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3349\/ymj.2015.56.4.1158","article-title":"Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Beh\u00e7et\u2019s Disease","volume":"56","author":"Park","year":"2015","journal-title":"Yonsei Med. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.berh.2016.07.005","article-title":"Advancements in the Management of Uveitis","volume":"30","author":"Schwartzman","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"204062231984788","DOI":"10.1177\/2040622319847881","article-title":"Effectiveness and Safety of Interferon \u03b12a as an Add-On Treatment for Refractory Beh\u00e7et\u2019s Uveitis","volume":"10","author":"Shi","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Beh\u00e7et\u2019s Uveitis Refractory to Conventional Treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00417-005-0005-8","article-title":"Risk and Prognostic Factors of Poor Visual Outcome in Behcet\u2019s Disease with Ocular Involvement","volume":"243","author":"Takeuchi","year":"2005","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmo"},{"key":"B31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/bjophthalmol-2015-307362","article-title":"Beh\u00e7et\u2019s Disease Ocular Attack Score 24 and Visual Outcome in Patients with Beh\u00e7et\u2019s Disease","volume":"100","author":"Tanaka","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of Interferon-Alfa Therapy in Patients with Beh\u00e7et Uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et Disease: An Analysis of 880 Patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0002-9394(14)72840-5","article-title":"Combined Cyclosporine and Corticosteroid Therapy for Sight-Threatening Uveitis in Beh\u00e7et\u2019s Disease","volume":"118","author":"Whitcup","year":"1994","journal-title":"Am. J. Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2017.1384026","article-title":"Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Beh\u00e7et\u2019s Uveitis Not Responding to Conventional Therapy","volume":"27","author":"Yang","year":"2019","journal-title":"Ocul. Immunol. Inflamm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.699903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T06:19:50Z","timestamp":1626675590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.699903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":35,"alternative-id":["10.3389\/fphar.2021.699903"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.699903","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"article-number":"699903"}}